

Non-QPP Measures

#	Measure ID	Measure Title	Definition	Type	Domain
1	AQUA3 (inverse)	Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys	Percentage of patients (boys) =< 18 years of age newly diagnosed with undescended testis or retractile testis with an order for ultrasound (scrotal or groin) placed	Process	Efficiency and Cost Reduction
2	AQUA8 (inverse)	Hospital re-admissions / complications within 30 days of TRUS Biopsy	Percentage of patients who had TRUS biopsy performed who had ≥24h after the biopsy): infection, hematuria, new antibiotic Rx after biopsy, or inpatient consultation within 30 days	Outcome	Patient Safety
3	AQUA12	Benign Prostate Hyperplasia: IPSS improvement after diagnosis	Percentage of patients with NEW diagnosis of clinically significant BPH who had IPSS (international prostate symptoms score) or AUASS (American urological association symptom score) improvement by ≥20%	Outcome	Person & Caregiver-Centered Experience Outcomes
4	AQUA13 (inverse)	Stress Urinary Incontinence (SUI): Revision surgery within 12 months of incontinence procedure	Percentage of women who undergo surgery for stress incontinence who require revision surgery within 12 months	Outcome	Effective Clinical Care
5	AQUA14 (inverse)	Stones: Repeat Shock Wave Lithotripsy (SWL) within 6 months of treatment	Percentage of patients who underwent endoscopic procedures following SWL	Outcome	Efficiency and Cost Reduction
6	AQUA15	Stones: Urinalysis documented 30 days before surgical stone procedures	Percentage of patients with a documented urinalysis 30 days before surgical stone procedures	Process	Patient Safety

Non-QPP Measures

#	Measure ID	Measure Title	Definition	Type	Domain
7	AQUA16	Non-Muscle Invasive Bladder Cancer: Repeat Transurethral Resection of Bladder Tumor (TURBT) for T1 disease	Percentage of patients with T1 disease, that had a second TURBT within 6 weeks of the initial TURBT	Process	Efficiency and Cost Reduction
8	AQUA17	Non-Muscle Invasive Bladder Cancer: Initiation of BCG within 3 months of diagnosis of high-grade T1 bladder cancer and/or CIS	Percentage of patients who initiate BCG treatment within 3 months of diagnosis of high-grade T1 bladder cancer and/or CIS	Process	Effective Clinical Care
9	AQUA18	Non-Muscle Invasive Bladder Cancer: Early surveillance cystoscopy within 4 months of initial diagnosis	Percentage of patients who receive surveillance cystoscopy within 4 months of TURBT for bladder cancer	Process	Effective Clinical Care
10	AQUA19 <i>(New for 2018)</i>	Diagnosis of Type of Azoospermia and Diagnostic Testing for Obstructive Azoospermia	Percentage of patients who had minimum necessary concepts discussed as part of diagnosis of azoospermia alone, to determine possibility of obstructive versus non-obstructive azoospermia and underwent diagnostic testing for obstructive azoospermia	Process	Effective Clinical Care
11	AQUA20 <i>(New for 2018)</i>	Genetic Testing of the Azoospermic Male	Percentage of patients with non-obstructive azoospermia due to primary testis failure who were offered genetic testing	Process	Effective Clinical Care
12	AQUA21 <i>(New for 2018)</i>	Appropriate Management of Obstructive Azoospermia	Percentage of obstructive azoospermia patients managed appropriately	Process	Effective Clinical Care

Non-QPP Measures

#	Measure ID	Measure Title	Definition	Type	Domain
13	AQUA22 <i>(New for 2018)</i>	Bone imaging and soft tissue imaging at the time of diagnosis of metastatic CRPC	Percentage of patients who receive bone imaging and soft tissue imaging at the time of diagnosis of metastatic CRPC	Process	Effective Clinical Care
14	AQUA23 <i>(New for 2018)</i>	Blood work for patients receiving abiraterone	Percentage of patients receiving abiraterone who receive monthly blood work and serum transaminases (ALT and AST) and bilirubin levels prior to starting treatment and every two weeks for the first three months of treatment and monthly thereafter	Process	Effective Clinical Care
15	AQUA24 <i>(New for 2018)</i>	Testosterone and PSA levels checked for CRPC patients	Percentage of patients on hormonal therapy who have their testosterone and PSA levels checked before starting treatment for CRPC	Process	Effective Clinical Care
16	AQUA25 <i>(New for 2018)</i>	Use of Prednisone for CRPC patients on abiraterone	Percentage of patients who are receiving abiraterone who are also receiving prednisone	Process	Effective Clinical Care
17	AQUA26 (inverse)	Benign Prostate Hyperplasia Care: Benign Prostate Hyperplasia <i>(Formerly AQUA5 & AQUA6 in 2017)</i>	Percentage of patients with new diagnosis of BPH who had a creatinine lab order placed or had a CT abdomen, MRI abdomen, ultrasound abdomen ordered or performed.	Process	Efficiency and Cost Reduction
18	AQUA27 <i>(New for 2018)</i>	Appropriate Testing for Vasectomy Patients	Percentage of patients where a Post Vasectomy Semen Analysis (PVSA) was ordered and confirmed sterility within 6 months of undergoing a vasectomy	Process	Effective Clinical Care

Non-QPP Measures

#	Measure ID	Measure Title	Definition	Type	Domain
19	AQUA28	Hypogonadism: Testosterone and hematocrit within 6 months of starting testosterone replacement (Formerly AQUA4 in 2017; added hematocrit in 2018)	Percentage of patients with hypogonadism, starting testosterone medication (any formulation of testosterone) or rec'd testosterone injection in clinic have testosterone level ordered and hematocrit ordered/reported within 6 months of first testosterone Rx or injection	Process	Effective Clinical Care
20	AQUA29	Prostate Cancer: Patient report of Urinary function after treatment (Formerly AQUA10 in 2017)	Percentage of patients who had a reported urinary function score at 12 months after treatment that is within 80% of the reported urinary function score at baseline (before treatment)	Outcome	Person & Caregiver-Centered Experience Outcomes
21	AQUA30	Prostate Cancer: Patient report of Sexual function after treatment (Formerly AQUA11 in 2017)	Percentage of patients who had a reported sexual function score at 24 months after treatment that is within 60% of the reported sexual function score at baseline (before treatment)	Outcome	Person & Caregiver-Centered Experience Outcomes
22	MUSIC4	Prostate Cancer: Active surveillance / watchful waiting for low-risk prostate cancer	Percentage of patients with low-risk prostate cancer receiving active surveillance or watchful waiting	Process	Effective Clinical Care
23	MUSIC10	Prostate Cancer: Confirmation Testing in low risk AS eligible patients	Percentage of low risk patients that are eligible for active surveillance who receive confirmation testing within 6 months of diagnosis	Process	Efficiency and Cost Reduction
24	MUSIC11	Prostate Cancer: Follow-Up Testing for patients on active surveillance for at least 30 months	Percentage of patients on active surveillance that have ≥ 2 tumor burden reassessments and 3 PSA tests in first 30 months since diagnosis	Process	Effective Clinical Care

QPP Measures

#	QPP #	Measure Title	Definition	Type	Domain
25	1*	Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)	Percentage of patient 18-75 years of age with diabetes who had hemoglobin A1c>9.0% during the measurement period	Intermediate Outcome	Effective Clinical Care
26	23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When indicated in ALL patients)	Percentage of surgical patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients, who had an order for Low Molecular Weight Heparin (LMWH), Low-Dose Unfractionated Heparin(LDUH), adjusted- dose warfarin, fondaparinux or mechanical prophylaxis to be given within 24 hours prior to incision time or within 24 hours after	Process	Patient Safety
27	46	Medication Reconciliation	Percentage of patients aged 65 years and older discharged from any inpatient facility (e.g. hospital, skilled nursing facility, or rehabilitation facility) and seen within 30 days following discharge in the office by the physician, prescribing practitioner, registered nurse, or clinical pharmacist providing on-going care who had a reconciliation of the discharge medications with the current medication list in the outpatient medical record documented.	Process	Communication & Care Coordination
28	47	Advance Care Plan	Percentage of patients aged 65 years and older who have an advance care plan or surrogate decision maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan	Process	Communication & Care Coordination

QPP Measures

#	QPP #	Measure Title	Definition	Type	Domain
29	48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	Percentage of female patients aged 65 years and older who were assessed for the presence or absence of urinary incontinence within 12 months	Process	Effective Clinical Care
30	50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	Percentage of female patients aged 65 years and older with a diagnosis of urinary incontinence with a documented plan of care for urinary incontinence at least once within 12 months	Process	Person & Caregiver- Centered Experience & Outcomes
31	102*	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer	Process	Efficiency and Cost Reduction
32	104	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist)	Process	Effective Clinical Care
33	110*	Influenza Immunization	Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization	Process	Community & Population Health
34	111*	Pneumococcal Vaccination Status for Older Adults	Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine	Process	Community & Population Health

QPP Measures

#	QPP #	Measure Title	Definition	Type	Domain
35	112*	Breast Cancer Screening	Percentage of women 50-74 years of age who had a mammogram to screen for breast cancer	Process	Effective Clinical Care
36	113*	Colorectal Cancer Screening	Percentage of patients 50 through 75 years of age who had appropriate screening for colorectal cancer	Process	Effective Clinical Care
37	117*	Diabetes: Eye Exam	Percentage of patients 18 - 75 years of age with diabetes who had a retinal or dilated eye exam by an eyecare professional during the measurement period or a negative retinal or dilated eye exam (no evidence of retinopathy) in the 12 months prior to the measurement period	Process	Effective Clinical Care
38	119*	Diabetes: Medical Attention for Nephropathy	The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period	Process	Effective Clinical Care
39	128*	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	Percentage of patients aged 18 years and older with a documented BMI during the current encounter or during the previous six months AND when the BMI is outside of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the encounter	Process	Community & Population Health

QPP Measures

#	QPP #	Measure Title	Definition	Type	Domain
40	130*	Documentation of Current Medications in the Medical Record	Percentage of specified visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications to the best of his/her knowledge and ability. This list must include ALL prescriptions, over-the- counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications' name, dosage, frequency and route of administration	Process	Patient Safety
41	131	Pain Assessment and Follow-Up	Percentage of visits for patients aged 18 years and older with documentation of a pain assessment using a standardized tool(s) on each visit AND documentation of a follow-up plan when pain is present	Process	Community & Population Health
42	134*	Preventive Care and Screening: Screening for Depression and Follow-Up Plan	Percentage of patients aged 12 years and older screened for depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen	Process	Community & Population Health
43	204*	Ischemic Vascular Disease (IVD): Use of Aspirin or another Antiplatelet	Percentage of patients 18 years of age and older who were diagnosed with acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had documentation of aspirin or another antiplatelet during the measurement period	Process	Effective Clinical Care

QPP Measures

#	QPP #	Measure Title	Definition	Type	Domain
44	226*	Preventive Care and Screening Tobacco Use: Screening and Cessation Intervention	Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user	Process	Community & Population Health
45	236*	Controlling High Blood Pressure	Percentage of patients 18 through 85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (< 140/90 mmHg) during the measurement period	Intermediate Outcome	Effective Clinical Care
46	265	Biopsy Follow-Up	Percentage of new patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient by the performing physician	Process	Communication & Care Coordination
47	317*	Preventive Care and Screening: Screening for High Blood Pressure and Follow	Percentage of patients aged 18 years and older seen during the reporting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated	Process	Community & Population Health
48	318*	Preventive Care and Falls: Screening for Future Fall Risk	Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period	Process	Community & Population Health
49	357	Surgical Site Infection	Percentage of patients aged 18 years and older who had a surgical site infection (SSI)	Outcome	Effective Clinical Care

QPP Measure

#	QPP #	Measure Title	Definition	Type	Domain
50	358	Patient-Centered Surgical Risk Assessment and Communication	Percentage of patients who underwent a non-emergency surgery who had their personalized risks of postoperative complications assessed by their surgical team prior to surgery using a clinical data-based, patient-specific risk calculator and who received personal discussion of those risks with the surgeon	Process	Person & Caregiver- Centered Experience & Outcomes
51	370*	Depression Remission at Twelve Months	The percentage of patients 18 years of age or older with major depression or dysthymia who reached remission 12 months (+/- 30 days) after an index visit	Outcome	Effective Clinical Care
52	431	Preventive Care and Screening Unhealthy Alcohol Use Screening & Brief Counseling	Percentage of patients aged 18 years and older who were screened at least once within the last 24 months for unhealthy alcohol use using a systematic screening method AND who received brief counseling if identified as an unhealthy alcohol user	Process	Community & Population Health
53	438*	Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	<p>Percentage of the following patients – all considered at high risk of cardiovascular events – who were on statin therapy during the performance period:</p> <ul style="list-style-type: none"> • Adults aged ≥ 21 years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR • Adults ≥ 21 years who ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level ≥ 190 mg/dl or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia; OR • Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189mg/dl 	Process	Effective Clinical Care